武田藥品因應愛爾蘭稅局裁決撥備5.7億美元
武田藥品表示,首財季將作出約630億日圓(約5.7億美元)的撥備,因愛爾蘭稅務上訴委員會維持藥廠Shire於2014年10月從美國藥廠AbbVie(ABBV.US)收到的違約金需要繳稅的決定。
武田藥品於2019年收購的Shire時收到愛爾蘭稅務局的稅務評估,要求對AbbVie放棄收購Shire時所支付的違約金徵稅,武田藥品已在2020年對該評估提出上訴。
武田藥品稱,今次上訴結果不會影響核心及基本業績,亦不會修改今財年的預測,計劃通過所有可用的法律手段來挑戰上訴結果,包括向愛爾蘭法院上訴。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.